EANS-News: SYGNIS Pharma AG / SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital measures

Heidelberg (euro adhoc) - SYGNIS´ reduction of share capital in a 3:1
ratio was entered in the commercial register

Heidelberg, 15 December 2010 - SYGNIS Pharma AG (Frankfurt:
LIO; ISIN DE0005043509; Prime Standard) today announced the
registration of the capital reduction in the commercial register
on the basis of the resolution of the Annual General Meeting
held on 30 November 2010. Hereby the share capital is reduced
from EUR 41,258,643 to EUR 13,752,881, allocated to 13,752,881
shares outstanding.

At the same time the implementation of the capital reduction on
the stock exchange and the consolidation of the shares in a 3:1
ratio were initiated. It is expected that the consolidation of the
shares will be completed by the end of December 2010. Due to this
process the trading of the SYGNIS shares on the stock exchange
will be temporarily suspended.

The purpose of this capital reduction is primarily to improve the
Company´s abilities to interact on the capital markets and to
open up financing alternatives, since the Company´s share price has
been below the nominal value of EUR 1 for a long period. It is
anticipated that this move will better support the development of the
shares.

About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,
is a specialty pharmaceutical company listed on the Prime Standard
of the German stock exchange. The Company is focused on the
research and development of innovative therapies for the
treatment of disorders of the Central Nervous System. SYGNIS´ core
projects are currently Acute Stroke for which SYGNIS´ lead clinical
programme is AX200 as well as the preclinical KIBRA-project for
the treatment of different forms of dementia. All these disorders
are characterized by the fact that, as the disease progresses,
nerve cells are damaged and die. Although there is great medical
demand, there are currently no or only inadequate treatment
options available. SYGNIS´ strategy for growth includes the
development of new products from its own research and through
in-licensing and acquisitions.

For further information please contact:
SYGNIS Pharma AG:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

### Disclaimer Some statements included in this press release,
relating neither to proven financial results nor other historical
data, should be viewed as forward- looking, i.e. not definite.
Such statements are mainly predictions of future results, trends,
plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by
other factors as a consequence of which the actual results, plans
and goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise
these statements in the light of new information or future results
or for any other reason. ###

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Franz-Werner Haas

Vice President Operations

+49 (0) 6221 454 812

franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade